1,167,350 Shares in DENTSPLY SIRONA Inc. $XRAY Acquired by Heartland Advisors Inc.

Heartland Advisors Inc. bought a new stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,167,350 shares of the medical instruments supplier’s stock, valued at approximately $12,386,000. Heartland Advisors Inc. owned about 0.59% of DENTSPLY SIRONA at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of XRAY. First Eagle Investment Management LLC raised its position in shares of DENTSPLY SIRONA by 3.2% during the fourth quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after purchasing an additional 458,744 shares during the period. Edmond DE Rothschild Holding S.A. purchased a new position in DENTSPLY SIRONA in the 2nd quarter worth about $47,780,000. UBS Group AG raised its holdings in DENTSPLY SIRONA by 63.7% during the 4th quarter. UBS Group AG now owns 1,701,980 shares of the medical instruments supplier’s stock worth $19,454,000 after buying an additional 662,000 shares during the period. Fiduciary Alliance LLC purchased a new stake in DENTSPLY SIRONA during the first quarter valued at about $4,607,000. Finally, Cibc World Market Inc. boosted its holdings in shares of DENTSPLY SIRONA by 120.7% in the fourth quarter. Cibc World Market Inc. now owns 1,184,303 shares of the medical instruments supplier’s stock worth $13,537,000 after buying an additional 647,763 shares during the period. Institutional investors own 95.70% of the company’s stock.

Insider Buying and Selling at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Brian P. Mckeon bought 10,000 shares of the firm’s stock in a transaction on Friday, June 12th. The stock was bought at an average cost of $10.12 per share, with a total value of $101,200.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company’s stock, valued at approximately $101,200. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael J. Barber purchased 15,175 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the purchase, the director owned 55,943 shares in the company, valued at $552,716.84. The trade was a 37.22% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 35,160 shares of company stock worth $351,179 over the last ninety days. 0.46% of the stock is currently owned by insiders.

DENTSPLY SIRONA Price Performance

XRAY opened at $10.92 on Friday. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of -3.97, a PEG ratio of 1.36 and a beta of 0.85. DENTSPLY SIRONA Inc. has a 1 year low of $9.40 and a 1 year high of $14.86. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 1.48. The stock has a fifty day moving average price of $12.02 and a 200 day moving average price of $11.80.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.35 by $0.17. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.The business had revenue of $898.00 million during the quarter, compared to analysts’ expectations of $889.93 million. During the same quarter in the previous year, the business posted $0.52 EPS. The firm’s quarterly revenue was down 4.1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts forecast that DENTSPLY SIRONA Inc. will post 1.41 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on XRAY shares. Barclays cut their price target on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a report on Thursday, June 4th. BMO Capital Markets reiterated a “market perform” rating and set a $13.00 price objective on shares of DENTSPLY SIRONA in a research report on Friday, August 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research note on Monday, August 3rd. Barrington Research set a $15.00 target price on DENTSPLY SIRONA in a report on Monday, August 10th. Finally, UBS Group decreased their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $13.38.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.